Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2021 / Articles / Mar / Lessons in Misadventure
Business & Regulation Advanced Medicine Profession Business & Trends

Lessons in Misadventure

"A half-baked strategy just might kill you."

By James Strachan 03/26/2021 1 min read

Share

I few months back, I went hiking in the English Peak District. The pre-panned route was tamer than expected, so we decided to follow another hiker who was scaling a small rapid with apparent ease. After about 30 minutes of climbing, we were close to the summit – all we had to do was navigate a ledge that sloped around the hill. But, as we climbed, the ledge narrowed. It was doable, but I really didn't fancy tiptoeing with a 30 foot drop below, so I made the executive decision to turnaround and retrace our steps. 

It got me thinking about leadership. A more experienced climber might've calculated the level of risk differently. And I'm sure we could've reached the the summit with better planning, equipment – and of course courage! So it was fascinating to read a blog (1) by Kristen Hege, senior vice president of Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb. Kristen is a CAR T pioneer, involved in some of the first trials in the late 1990s as Bruce Levine pointed out (2) – and evidently made of sterner stuff than me!

She tells the story of her "misadventure" in the snowy High Sierras of Northern California. Her lessons learned are distilled below, but I encourage you to read the full article. To whet your appetite: "Even if I stumbled and fell in the rapids and my head was held under by the force of the water, the rope would ferry me across to the far side before I had time to drown."

Kristen's lessons learned:

"First, one can never be too prepared.  We now carry a real rope on our backpacking trips, and I have watched countless you-tube videos on rope-assisted creek crossings and have learned how to better assess the risk of water crossings.

"Second, when faced with unexpected setbacks and difficult choices, where all solutions are imperfect, it is best to sleep on it and tackle the problem again in the morning with a fresh perspective.

"Third, taking the time to compile and vet all possibilities and risk mitigation strategies with as many views as possible is essential, as a half-baked strategy just might kill you.

"Fourth, once you have settled on a path forward, we all have different mental strategies to ensure flawless execution in a high stress environment. Find your own path, whether it be temporarily locking the door on free-floating anxiety until the risk has passed or using that anxiety to bring out your best self, whatever it is, find what works for you and then practice it.

"Finally, don’t let challenges and setbacks get you down; they often become our most cherished memories. Perseverance is crucial."

This article is based on a recent introduction to The Cell + Gene Curator - a weekly newsletter covering the latest news and research in the cell and gene therapy space. Subscribe for free at: https://www.texerenewsletters.com/cellandgene  

Formulation and Characterization Strategies for Gene Therapies

Gene therapy product formulation studies are currently limited in scope. Hear our expert discuss how we're working towards establishing formulation selection criteria using traditional techniques and evaluating novel methodologies.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Plengegen, "Guest blog: Lessons Learned from Misadventure - Kristen Hege" (2021). Available at: https://bit.ly/3tO254p 
  2. Bruce Levine (2021). Available at: https://bit.ly/3vVB8gX 

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

Don’t Forget CDx Developers
Advanced Medicine
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business Practice Standards & Regulation Trends & Forecasts Advanced Medicine
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.